NOTCH3 Protein
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">NOTCH3 (Notch Receptor 3)</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>[NOTCH3](/genes/notch3)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q9UM47" target="_blank">Q9UM47</a></td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Notch 3</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>270 kDa (full-length)</td>
</tr>
<tr>
<td class="label">Length</td>
<td>2,321 amino acids</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Plasma membrane, Endoplasmic reticulum</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Vascular smooth muscle cells, Pericytes, some neurons</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>[CADASIL](/diseases/cadasil), [Vascular Dementia](/diseases/vascular-dementia), [Alzheimer's Disease](/diseases/alzheimers-disease)</td>
</tr>
</table>
NOTCH3 Protein
Overview
Mermaid diagram (expand to render)
NOTCH3 is a single-pass transmembrane receptor belonging to the Notch family of signaling proteins (NOTCH1-4 in mammals). It transduces critical signals between adjacent cells through conserved ligand (Delta/Jagged)-mediated interactions, playing essential roles in cell fate determination, vascular development, and tissue homeostasis["@gridley1997"]. Unlike other Notch receptors, NOTCH3 exhibits unique expression patterns and is predominantly expressed in vascular smooth muscle cells and [pericytes](/cell-types/pericytes), where it maintains vascular integrity and function.
Mutations in NOTCH3 cause CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), the most common hereditary form of vascular dementia and the leading cause of inherited stroke in adults. This condition affects small arteries in the brain, leading to recurrent subcortical ischemic strokes, cognitive decline, and progressive disability. Beyond CADASIL, emerging research suggests that NOTCH3 may play broader roles in neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease)[@marvie2004].
Structure and Biochemistry
Primary Structure
NOTCH3 is a large type I transmembrane receptor composed of 2,321 amino acids with a molecular weight of approximately 270 kDa. The protein is organized into three major structural domains:
Extracellular Domain (NECD, amino acids 1-1,643):
- Epidermal Growth Factor-like (EGF) repeats: 34 EGF-like repeats, 6 of which are calcium-binding (cbEGF)
- LIN-12 Notch repeats (LNR): 3 LNR domains that prevent ligand-independent activation
- Multiple cysteine residues: Form disulfide bonds essential for structural stability
Transmembrane Domain (amino acids 1,644-1,666):
- Single-pass transmembrane helix
- Anchors receptor in the plasma membrane
- Site of proteolytic cleavage (S2)
Intracellular Domain (NICD, amino acids 1,667-2,321):
- RBP-Jκ-associated module (RAM): Binds transcriptional co-activators
- Ankyrin repeats: 6 ankyrin repeats for protein-protein interactions
- Transactivation domain (TAD): Responsible for transcriptional activation
- PEST domain: Regulates protein stability
Domain Architecture
[EGF-like repeats] - [LIN-12 repeats] - [TM] - [RAM] - [Ankyrin] - [TAD] - [PEST]
1-1643 1644-1666 1667-1757 1757-1936 1936-2131 2131-2321
Post-Translational Modifications
NOTCH3 undergoes several important post-translational modifications:
- N-linked glycosylation: Extensive glycosylation in EGF repeats affects ligand binding
- O-fucosylation: Essential for Notch signaling
- Proteolytic processing: Sequential cleavages generate active fragments
Proteolytic Activation
NOTCH3 activation involves a two-step proteolytic process:
S1 cleavage (constitutive): Furin-like convertase cleaves in the extracellular domain
S2 cleavage (ligand-dependent): ADAM10 or ADAM17 cleaves at the membrane proximal site
S3 cleavage (ligand-dependent): γ-secretase releases the NICD for nuclear translocation
Normal Physiological Function
Expression Pattern
NOTCH3 exhibits a distinctive expression pattern:
Primary Expression:
- Vascular smooth muscle cells (highest levels)
- [Pericytes](/cell-types/pericytes) in the cerebral vasculature
- Some populations of astrocytes
Lower Expression:
- Certain neuronal populations
- Some immune cells
- Limited expression in other tissues
Vascular Function
NOTCH3 plays essential roles in vascular homeostasis:
Vascular Development:
- Essential for blood vessel formation during embryogenesis
- Regulates arterial-venous specification
- Controls vascular smooth muscle cell investment[@domenga2004]
Vascular Maintenance:
- Maintains vascular smooth muscle cell contractility
- Regulates blood flow through vessel tone
- Supports endothelial-pericyte interactions
Notch Signaling Pathway
Canonical Notch Signaling:
Ligand binding: Delta-like (DLL1, DLL3, DLL4) or Jagged (JAG1, JAG2) ligands on adjacent cells
Proteolytic cleavage: Sequential S2 and S3 cleavages
NICD release: Active intracellular domain translocates to nucleus
Transcription: NICD binds RBP-Jκ (CSL) to activate target genesTarget Genes:
- Hes family (Hes1, Hes5)
- Hey family (Hey1, Hey2, HeyL)
- Cell cycle regulators
- Extracellular matrix proteins
Role in the Blood-Brain Barrier
NOTCH3 is important for blood-brain barrier (BBB) function:
- Regulates endothelial-pericyte communication
- Maintains tight junction integrity
- Controls BBB development and maintenance
Role in CADASIL
Disease Overview
CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) is the most common hereditary vascular dementia, affecting approximately 1 in 50,000 individuals worldwide. It is caused by dominant mutations in the NOTCH3 gene, leading to progressive degeneration of small cerebral arteries[@joutel1996].
Clinical Features:
- Migraine with aura (often earliest symptom)
- Recurrent subcortical ischemic strokes
- Progressive cognitive decline and dementia
- Mood disorders (depression, apathy)
- White matter lesions on MRI
- Subcortical hemorrhages
Disease Course:
- Onset typically 30-50 years
- Progressive decline over 10-30 years
- Mean survival 20-30 years after onset
- Leading to severe disability and premature death
Pathogenic Mechanisms
NOTCH3 mutations cause CADASIL through several mechanisms:
1. Accumulation of NOTCH3 Extracellular Domain:
- Mutant NOTCH3 accumulates in vessel walls
- Forms granular osmiophilic deposits (GOM)
- Disrupts vascular smooth muscle cell function
2. Impaired Vascular Function:
- Reduced smooth muscle cell contractility
- Altered blood flow regulation
- Increased susceptibility to ischemia
3. Degeneration of Vascular Smooth Muscle Cells:
- Loss of smooth muscle cells in small arteries
- Vessel wall thickening
- Reduced vascular reserve capacity
4. Blood-Brain Barrier Disruption:
- Impaired endothelial function
- Pericyte dysfunction
- Enhanced leukocyte infiltration[@ruchoux2003]
Mutations
Over 200 different NOTCH3 mutations have been identified in CADASIL patients:
| Mutation Type | Percentage | Common Examples |
|--------------|------------|-----------------|
| Missense (cysteine) | ~70% | R587C, C183R, C428S |
| Missense (non-cysteine) | ~15% | R90K, P496L |
| Splice site | ~10% | IVS19-2A>G |
| Small deletions | ~5% | Various |
Cysteine mutations in EGF-like repeats are most common, disrupting disulfide bond formation and protein folding.
Pathology
Key Pathological Features:
Granular osmiophilic deposits (GOM): Electron-dense granules in vessel walls
Smooth muscle cell degeneration: Loss and degeneration of VSMCs
Basal membrane thickening: Accumulation of extracellular matrix
Lacunar infarcts: Small subcortical strokes
White matter lesions: Demyelination and gliosis
Role in Alzheimer's Disease
Interactions with AD Pathology
NOTCH3 may influence [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis through several mechanisms:
Amyloid Processing:
- γ-secretase processes both NOTCH and APP
- Competition for γ-secretase may affect Aβ production
- NOTCH signaling affects APP gene expression[@shi2020]
Vascular Contributions:
- NOTCH3 dysfunction affects cerebral vasculature
- May contribute to cerebral amyloid angiopathy (CAA)
- Vascular dysfunction as a risk factor for AD
Genetic Associations
- NOTCH3 variants may modify AD risk
- Some polymorphisms associated with earlier onset
- Interaction with other AD risk genes
Role in Parkinson's Disease
Emerging Evidence
Recent studies suggest potential roles for NOTCH3 in [Parkinson's disease](/diseases/parkinsons-disease):
Expression Changes:
- Altered NOTCH3 expression in PD brains
- Potential involvement in nigral neuron maintenance
- May affect glial cell function
Neuroinflammation:
- NOTCH3 signaling in microglia
- Potential modulation of neuroinflammatory responses
- Interaction with Parkinsonian pathology[@halliday2016]
Therapeutic Strategies
Current Approaches
| Strategy | Status | Description |
|----------|--------|-------------|
| γ-secretase inhibitors | Not beneficial | Block NOTCH cleavage but cause side effects |
| Notch modulators | Research | Agonists/antagonists of downstream signaling |
| Anti-NOTCH3 antibodies | Preclinical | Target mutant protein for clearance |
| Gene therapy | Future | Correct mutations or provide wild-type |
Emerging Therapies
1. Antibody-Based Approaches:
- Monoclonal antibodies targeting NOTCH3 extracellular domain
- Enhanced clearance of mutant protein
- Prevention of toxic accumulation
2. Small Molecule Modulators:
- γ-secretase modulators (GSM) that preferentially affect APP
- NOTCH-sparing GSMs in development
3. Vascular Protective Strategies:
- Strategies to improve cerebral blood flow
- Endothelial function enhancers
- Pericyte-stabilizing compounds
CADASIL-Specific Approaches
Sarafan:
- Investigational drug for CADASIL
- Targets NOTCH3 signaling
- Currently in preclinical/early clinical development
Symptomatic Treatments:
- Antiplatelet agents for stroke prevention
- Blood pressure control
- Cognitive enhancers
- Management of migraine
Animal Models
Mouse Models
Notch3 knockout mice:
- Viable but with vascular defects
- Impaired vascular smooth muscle cell function
- Useful for studying NOTCH3 function
CADASIL model mice:
- Transgenic mice expressing mutant NOTCH3
- Recapitulate key pathological features
- GOM formation, smooth muscle degeneration
- Useful for therapeutic testing
Other Models
- Zebrafish: Notch3 in vascular development
- Drosophila: Evolutionary conserved functions
Biomarkers
Genetic Testing
- NOTCH3 sequencing for CADASIL diagnosis
- Identification of family-specific mutations
- Predictive testing for at-risk individuals
Clinical Biomarkers
- MRI: White matter hyperintensities, lacunar infarcts
- Magnetic resonance angiography (MRA): Vessel wall imaging
- CSF markers: May reflect disease activity
Emerging Biomarkers
- NOTCH3 extracellular domain in CSF
- Vessel-derived biomarkers
- Imaging of GOM deposits
Cross-References
- [NOTCH3 Gene](/genes/notch3)
- [CADASIL](/diseases/cadasil)
- [Vascular Dementia](/diseases/vascular-dementia)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)
- [Vascular Smooth Muscle Cells](/cell-types/vascular-smooth-muscle-cells)
- [Pericytes](/cell-types/pericytes)
Key Publications
[Joutel A, et al. Notch3 mutations in CADASIL. Nature. 1996.](https://pubmed.ncbi.nlm.nih.gov/8852660/)
[Gridley T. Notch genes in vertebrate development. Cell. 1997.](https://pubmed.ncbi.nlm.nih.gov/9275203/)
[Kopan R, et al. Notch signaling. Cell. 2004.](https://pubmed.ncbi.nlm.nih.gov/15469841/)
[Domenga V, et al. Notch3 is required for vascular development. Development. 2004.](https://pubmed.ncbi.nlm.nih.gov/15286739/)
[Marvie P, et al. Notch3 and Alzheimer's disease. Neurobiol Aging. 2004.](https://pubmed.ncbi.nlm.nih.gov/12646242/)
[Tikka S, et al. Notch3 and pericytes in CADASIL. J Cereb Blood Flow Metab. 2014.](https://pubmed.ncbi.nlm.nih.gov/24785740/)
[Halliday G, et al. NOTCH3 in Parkinson disease. Acta Neuropathol. 2016.](https://pubmed.ncbi.nlm.nih.gov/27221046/)
[Shi F, et al. Notch3 and amyloid processing. Mol Neurobiol. 2020.](https://pubmed.ncbi.nlm.nih.gov/31754920/)
External Links
- UniProt: [Q9UM47](https://www.uniprot.org/uniprot/Q9UM47)
- AlphaFold: [NOTCH3](https://alphafold.ebi.ac.uk/entry/Q9UM47)
- NCBI Gene: [NOTCH3](https://www.ncbi.nlm.nih.gov/gene/4854)
- OMIM: [600276](https://www.omim.org/entry/600276)
- GeneCards: [NOTCH3](https://www.genecards.org/cgi-bin/carddisp.pl?gene=NOTCH3)
- CADASIL Foundation: [Information and resources](https://www.cadasil.org/)
References
[@gridley1997]: Gridley, T. [Notch genes in vertebrate development](https://pubmed.ncbi.nlm.nih.gov/9275203/). Cell. 1997.
[@kopan2004]: Kopan, R. et al. [Notch signaling](https://pubmed.ncbi.nlm.nih.gov/15469841/). Cell. 2004.
[@domenga2004]: Domenga, V. et al. [Notch3 is required for vascular development](https://pubmed.ncbi.nlm.nih.gov/15286739/). Development. 2004.
[@joutel1996]: Joutel, A. et al. [CADASIL: Notch3 mutations](https://pubmed.ncbi.nlm.nih.gov/8852660/). Nature. 1996.
[@marvie2004]: Marvie, P. et al. [Notch3 and Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/12646242/). Neurobiology of Aging. 2004.
[@ruchoux2003]: Ruchoux MM, et al. [The vascular wall in CADASIL](https://pubmed.ncbi.nlm.nih.gov/14503660/). Acta Neurol Belg. 2003.
[@halliday2016]: Halliday G, et al. [NOTCH3 in Parkinson disease](https://pubmed.ncbi.nlm.nih.gov/27221046/). Acta Neuropathol. 2016.
[@shi2020]: Shi F, et al. [Notch3 and amyloid processing in Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/31754920/). Mol Neurobiol. 2020.
See Also
- [Gap Analysis & Research Strategy](/wiki/gaps-gap-analysis) — activates
- [Riluzole ALS Trials](/wiki/clinical-trials-riluzole-als) — activates
- [Riluzole ALS Trials](/wiki/clinical-trials-riluzole-als) — associated_with
- [Riluzole ALS Trials](/wiki/clinical-trials-riluzole-als) — contributes_to
Pathway Diagram
The following diagram shows the key molecular relationships involving NOTCH3 Protein discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)